Hangzhou Tigermed Consulting Co., Ltd (HNGZY)
- Previous Close
4.1400 - Open
4.1400 - Bid 2.0500 x --
- Ask 29.4500 x --
- Day's Range
4.1400 - 4.1400 - 52 Week Range
4.1400 - 7.7800 - Volume
1,200 - Avg. Volume
25 - Market Cap (intraday)
6.942B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
27.60 - EPS (TTM)
0.1500 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield 0.08 (1.93%)
- Ex-Dividend Date Jun 11, 2024
- 1y Target Est
--
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
www.tigermedgrp.com9,701
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: HNGZY
View MorePerformance Overview: HNGZY
Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HNGZY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HNGZY
View MoreValuation Measures
Market Cap
6.94B
Enterprise Value
7.23B
Trailing P/E
26.97
Forward P/E
17.09
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.81
Price/Book (mrq)
1.23
Enterprise Value/Revenue
7.69
Enterprise Value/EBITDA
22.85
Financial Highlights
Profitability and Income Statement
Profit Margin
14.10%
Return on Assets (ttm)
2.77%
Return on Equity (ttm)
4.19%
Revenue (ttm)
6.8B
Net Income Avi to Common (ttm)
958.67M
Diluted EPS (ttm)
0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.04B
Total Debt/Equity (mrq)
17.00%
Levered Free Cash Flow (ttm)
-10.74M